Nemaura Medical Set to Join the Russell 2000® Index and Russell 3000® Index
June 09 2020 - 8:30AM
Business Wire
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the
“Company”), a medical technology company focused on developing
micro-systems-based wearable diagnostic devices and currently
commercializing sugarBEAT®, its non-invasive and flexible
continuous glucose monitor (“CGM”), together with BEAT®diabetes, a
planned health subscription service designed to help people with
Type 2 diabetes and prediabetes through personalized lifestyle
coaching, today announced the Company is set to join the small cap
Russell 2000® Index and the broad-market Russell 3000® Index at the
conclusion of this year’s reconstitution of the Russell stock
indexes, effective after the U.S. stock market opens on Monday,
June 29, 2020, according to a preliminary list of additions posted
June 5, 2020.
“Inclusion in the Russell Indexes is an important milestone and
will increase the overall awareness and exposure of our stock
within the investment community,” stated Dr. Faz Chowdhury, CEO of
Nemaura. “Broader exposure to the investment community comes at an
ideal time for Nemaura as we move forward with product sales in the
coming months and quarters.”
The annual reconstitution of the broad-market Russell 3000®
Index captures 3,000 of the largest U.S. stocks, ranking them by
total market capitalization. The largest 1,000 companies in this
ranking comprise the Russell 1000® Index and the next 2,000
companies constitute the Russell 2000® Index, which together
comprise the Russell 3000® Index. FTSE Russell determines
membership for its Russell US Indexes primarily by objective,
market-capitalization rankings and style attributes. Based on its
market capitalization, the Company qualified for membership in the
Russell 2000® index, which means automatic inclusion in the Russell
3000® Index as well as the appropriate growth and value style
indexes. Membership remains in effect for one year until the next
annual reconstitution.
Russell US Indexes are part of FTSE Russell, a leading global
index provider, and are widely used by investment managers and
institutional investors as the basis for index funds and as
benchmarks for active investment strategies. FTSE Russell reports
that approximately $9 trillion in assets are benchmarked against
Russell US Indexes. For more information on the Russell 3000® Index
and Russell 2000® Index and the Russell US Indexes reconstitution,
visit the “Russell Reconstitution” section at FTSE Russell
website.
About FTSE Russell
FTSE Russell is a leading global provider creating and managing
a wide range of indexes, data and analytic solutions to meet client
needs across asset classes, style and strategies. Covering 98% of
the investable market, FTSE Russell indexes offer a true picture of
global markets, combined with the specialist knowledge gained from
developing local benchmarks around the world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $16
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell
indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by the London
Stock Exchange Group.
For more information, visit www.ftserussell.com.
About Nemaura Medical, Inc.:
Nemaura Medical, Inc. (NMRD), is a medical technology company
commercializing BEAT®diabetes, a health subscription service
designed to help people with diabetes and prediabetes better manage
diabetes and reverse Type 2 diabetes or prevent diabetes through
1-on-1 lifestyle coaching and behavior driven by real time
continuous glucose monitoring (CGM) and daily glucose trend data
provided by sugarBEAT®, a non-invasive and flexible CGM.
For more information visit: www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura’s ongoing studies,
including the safety and efficacy of Nemaura’s sugarBEAT® system,
the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
sugarBEAT®, the availability of substantial additional equity or
debt capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
sugarBEAT®. These and other risks and uncertainties are identified
and described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Nemaura undertakes no obligation to
publicly update or revise any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200609005454/en/
Investor Contact: Dave Gentry, CEO RedChip Companies
Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498
dave@redchip.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024